Show simple item record

dc.contributor.authorKaratoprak, Cumali
dc.contributor.authorKılıçarslan, Rukiye
dc.contributor.authorÇakırca, Mustafa
dc.contributor.authorAydın, Sinem
dc.contributor.authorÖzkan, Tuba
dc.contributor.authorZorlu, Mehmet
dc.contributor.authorKıskaç, Muhammet
dc.date.accessioned2019-12-24T07:15:17Z
dc.date.available2019-12-24T07:15:17Z
dc.date.issued2019en_US
dc.identifier.citationKaratoprak, C., Kılıçarslan, R., Çakırcı, M., Aydın, S., Özkan, T. ... Kıskaç, M. (2019). Effects of 18-month vildagliptin treatment on portal vein pressure and hepatosteatosis. Bezmialem Science, 7(4), 317-321. https://doi.org/10.14235/bas.galenos.2019.2892en_US
dc.identifier.issn2148-2373
dc.identifier.urihttps://doi.org/10.14235/bas.galenos.2019.2892
dc.identifier.urihttps://hdl.handle.net/20.500.12511/4633
dc.description.abstractObjective: Patients with type 2 diabetes have an increased tendency to develop hepatosteatosis. The effects of drugs used to treat diabetes on the liver, regardless of the disease, are unknown.The aim of this study was to investigate the effects of vildagliptin, a dipeptidyl peptidase-4 inhibitor, on the portal vein pressure and hepatosteatosis in patients with type 2 diabetes in the 18 months of follow-up. Methods: Patients to whose treatment vildagliptin was added while they were on therapy with metformin and gliclazide for type 2 DM the vildagliptin group were included. As the control group, 49 patients with type 2 DM treated with metformin and gliclazide were included. These patients were followed up for 18 months. These patients were followed for 18 months and their pre-treatment and post-treatment examinations were repeated. Portal vein diameter, portal vein flow and portal vein velocity were calculated to evaluate portal vein pressure with the same Doppler ultrasonography (US) by the same radiologist. In the same session, the liver steatosis stage of all patients was evaluated with US and recorded. The data before treatment and the data 18 months after treatment were compared. Results: Nineteen patients completed the study in the study group, while 10 patients completed the study in the control group. A significant increase in portal vein flow velocity and vein diameter was found in the study group when portal vein parameters were compared before and after treatment (p=<0.001, p=0.035, respectively). There was no significant difference in portal vein flow volume. In the control group, no significant changes in flow velocity and flow volume were detected, although there was a significant increase in portal vein diameter (p=0.04, p=0.07, p=0.14, respectively). There were no significant changes in vildagliptin group before and after treatment in terms of hepatosteatosis (p=0.41). There were no significant changes between control and study groups in terms of hepatosteatosis after 18 months of treatment. Conclusion: As a result, we did not find any significant changes in the parameters of portal vein pressure with vildagliptin use. We think that vildagliptin has no effect on hepatosteatosis.en_US
dc.language.isoengen_US
dc.publisherBezmialem Vakif Universityen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDi-Peptidyl Peptidase 4 Inhibitorsen_US
dc.subjectVildagliptinen_US
dc.subjectPortal Vein Pressureen_US
dc.subjectHepatosteatosisen_US
dc.subjectTip 2 Diabetes Mellitusen_US
dc.titleEffects of 18-month vildagliptin treatment on portal vein pressure and hepatosteatosisen_US
dc.typearticleen_US
dc.relation.journalBezmialem Scienceen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Radyoloji Ana Bilim Dalıen_US
dc.authorid0000-0002-6195-3564en_US
dc.identifier.volume7en_US
dc.identifier.issue4en_US
dc.identifier.startpage317en_US
dc.identifier.endpage321en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.14235/bas.galenos.2019.2892en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record